Posted by Michael Wonder on 17 Sep 2017
CSL Behring announces FDA approval of Privigen [immune globulin intravenous (human), 10% liquid] for the treatment of chronic inflammatory demyelinating polyneuropathy in adults
14 September 2017 - Privigen shown to improve functional abilities in patients with a rare neurological condition.
CSL Behring today announced that the U.S. FDA has approved Privigen [immune globulin intravenous (human), 10% liquid] for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.
CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage.
